Last reviewed · How we verify
GSK233705 and GW642444
GSK233705 and GW642444 is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK233705 and GW642444 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD (PHASE2)
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects. (PHASE1)
- A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK233705 and GW642444 CI brief — competitive landscape report
- GSK233705 and GW642444 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK233705 and GW642444
What is GSK233705 and GW642444?
GSK233705 and GW642444 is a Small molecule drug developed by GlaxoSmithKline.
Who makes GSK233705 and GW642444?
GSK233705 and GW642444 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK233705 and GW642444 in?
GSK233705 and GW642444 is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: GSK233705 and GW642444 vs similar drugs
- Pricing: GSK233705 and GW642444 cost, discount & access